Brokerages Set Lifecore Biomedical, Inc. (NASDAQ:LFCR) Target Price at $8.00

Lifecore Biomedical, Inc. (NASDAQ:LFCR) has been given a consensus recommendation of “Hold” by the five research firms that are presently covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation, two have given a hold recommendation and two have assigned a buy recommendation to the company. The average 12 month target price among analysts that have covered the stock in the last year is $8.00.

A number of equities research analysts recently commented on LFCR shares. KeyCorp started coverage on shares of Lifecore Biomedical in a research report on Wednesday, September 3rd. They issued a “sector weight” rating for the company. Wall Street Zen raised Lifecore Biomedical from a “sell” rating to a “hold” rating in a report on Saturday, August 16th. Finally, Weiss Ratings restated a “sell (d)” rating on shares of Lifecore Biomedical in a research note on Saturday, September 27th.

Lifecore Biomedical Trading Down 1.1%

NASDAQ:LFCR opened at $6.98 on Friday. Lifecore Biomedical has a 12-month low of $4.33 and a 12-month high of $8.85. The company has a current ratio of 2.84, a quick ratio of 1.77 and a debt-to-equity ratio of 113.76. The stock’s 50 day simple moving average is $7.43 and its 200-day simple moving average is $7.11. The firm has a market cap of $261.51 million, a P/E ratio of -5.33 and a beta of 0.62.

Lifecore Biomedical (NASDAQ:LFCR) last posted its quarterly earnings data on Thursday, August 7th. The company reported ($0.10) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.01). The firm had revenue of $36.44 million during the quarter, compared to analysts’ expectations of $35.36 million. Lifecore Biomedical had a negative net margin of 31.70% and a negative return on equity of 846.51%. Lifecore Biomedical has set its FY 2026 guidance at EPS. Equities analysts anticipate that Lifecore Biomedical will post -0.91 EPS for the current year.

Hedge Funds Weigh In On Lifecore Biomedical

Large investors have recently made changes to their positions in the stock. GAMMA Investing LLC boosted its holdings in Lifecore Biomedical by 1,839.7% during the first quarter. GAMMA Investing LLC now owns 3,569 shares of the company’s stock worth $25,000 after buying an additional 3,385 shares in the last quarter. Summit Securities Group LLC acquired a new stake in shares of Lifecore Biomedical during the 1st quarter valued at approximately $26,000. Hurley Capital LLC purchased a new stake in shares of Lifecore Biomedical during the 1st quarter worth approximately $35,000. State of Wyoming acquired a new stake in shares of Lifecore Biomedical in the 2nd quarter worth approximately $69,000. Finally, The Manufacturers Life Insurance Company purchased a new position in Lifecore Biomedical in the 2nd quarter valued at approximately $88,000. Hedge funds and other institutional investors own 83.36% of the company’s stock.

Lifecore Biomedical Company Profile

Lifecore Biomedical, Inc, together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.